AlphaStroke is a fast and accurate early detection device for Stroke and Large Vessel Occlusions (LVO), a severe stroke with a different standard of care that is available at far fewer hospitals. AlphaStroke will improve patient outcomes by decreasing time to treatment of these patients and increasing the number of patients eligible for the gold standard of care because such interventions are time-limited. Hospital volumes of these reimburseable stroke interventions will increase. Finally, AlphaStroke lowers the cost of healthcare in the US and abroad by decreasing the rate of inter-hospital transfers, improving patient o utcomes and reducing the portion of patients that need rehabilitation. AlphaStroke is a portable, durable EEG-based device that uses specially designed disposable electrode caps that are easily placed on a patient’s head. AlphaStroke then uses proprietary machine-learning derived algorithms to detect LVO/Stroke-specific electrical biomarkers in the brain. There are multiple markets with multiple users, but the first go-to-market users are emergency medical technicians (EMTs) and paramedics, and the first indication is for LVO. Instead of administering subjective, difficult-to-interpret clinical exams, first responders using AlphaStroke receive a clear binary output (“Likely LVO” or “Unlikely LVO”).